Isocyanate‐Modified Melatplatin(IV) Enhances Antitumor Efficacy via TCF4/COL6A3‐Mediated Extracellular Matrix Remodeling and cGAS‐STING Pathway Activation in Bladder Cancer
ABSTRACT Cisplatin (CDDP) chemosensitivity and severe toxicity severely limit its clinical application in muscle‐invasive bladder cancer (MIBC) and non‐muscle‐invasive bladder cancer (NMIBC). To address these unmet clinical needs, we synthesized a series of melatonin‐conjugated platinum(IV) prodrugs functionalized with...